表紙:分子乳房画像診断の世界市場-2023年~2030年
市場調査レポート
商品コード
1374854

分子乳房画像診断の世界市場-2023年~2030年

Global Molecular Breast Imaging Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 187 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.08円
分子乳房画像診断の世界市場-2023年~2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

分子乳房画像診断は、シンチマンモグラフィ、核医学乳房撮影、乳房特異的ガンマイメージングとも呼ばれ、乳腺組織が密な女性の乳がんを同定するために使用される、先進的でFDA認可の画像技術です。分子乳房画像診断では、特殊なカメラと少量の放射性トレーサーを用いて、組織の活性の違いにスポットライトを当て、健康で密な組織と乳房の不整とを区別します。高精度の画像検査であり、がん細胞を見逃す可能性は低いです。

さらに、少量の放射性トレーサーを静脈ラインから患者に投与します。トレーサーは、がん細胞を含む急速に分裂する細胞に速やかに吸収され、画像結果に強調表示されます。患者は、マンモグラフィ装置と同様の特別な台の上に乳房を置きます。乳房は特殊なガンマカメラで高画質の画像を撮影するために軽く圧迫されますが、この軽い圧迫が不快感を与えることはありません。ガンマカメラは乳房の組織活動を約20分間記録します。

市場力学:促進要因

乳がん検診における分子乳房画像診断の採用増加

乳がん検診への分子乳房画像診断の採用が増加していることが、予測期間中の市場を牽引するとみられます。分子乳房画像診断は、特に乳腺組織が緻密な女性において、乳がんを検出する感度が高いことで知られています。マンモグラフィだけでは見逃される可能性のある腫瘍を特定するのに役立ちます。この精度の向上は、分子乳房画像診断の普及の大きな原動力となっています。

さらに、分子乳房画像診断は、マンモグラフィと並ぶ補完的な検診ツールとして使用されることも多いです。また、マンモグラフィで決定的な結果が得られない場合や追加情報が必要な場合、この画像診断技術は、がん診断の見逃しや遅れのリスクを低減することにより、貴重な洞察を提供することができます。

この画像技術の継続的な進歩により、より身近で使いやすいものとなっています。デジタルガンマカメラの開発や、より快適な撮像方法の開発など、これらの技術的向上により、より魅力的な選択肢となっています。乳がんの家族歴や、BRCA1やBRCA2のような既知の遺伝子変異を持つ患者さんなど、リスクの高い患者さんに推奨されることが多いです。より早い段階でがんを発見できることは、こうした患者にとって救命につながります。

例えば、2021年2月9日、スマートブレストコーポレーションはFoxSemicon Integrated Technologies, Inc.(FITI)と提携し、分子乳房画像診断(MBI)システムを製造すると発表しました。FITIはスマートブレストに多額の投資を行っており、スマートブレストが最近買収した2つのMBIシステム、GEヘルスケアDiscovery NM 750bとディロン・テクノロジーズD6800の製造委託先となります。スマートブレストは、この2つのシステムをそれぞれEVE CLEAR SCAN e750およびe680としてリブランドする予定です。スマートブレストとFITIは共同で、革新的で費用対効果の高い次世代MBIシステムを開発・製造し、がんの早期発見の有効性をさらに高め、普及を拡大していきます。

さらに、乳がんの有病率の増加、乳房用の新規かつ高度な分子イメージング技術に対するFDA承認の増加、より高度な装置を開発するための臨床試験の増加、分子乳房画像診断装置の開発に対する意識の高まりと進歩が、予測期間にわたって市場を牽引すると予想される要因です。

阻害要因

分子乳房画像診断に関連する合併症、このイメージング技術に関連する高コスト、この検査はすべてのがんを検出できるわけではないこと、分子乳房画像診断に含まれるトレーサーはアレルギー反応を起こす可能性があること、といった要因が市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 乳がん検診の普及拡大
    • 抑制要因
      • 分子乳房画像診断に伴う合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ
  • DMIの見解

第6章 COVID-19分析

第7章 設計タイプ別

  • 放射性トレーサー
  • ガンマカメラ

第8章 モダリティ別

  • シングルヘッドガンマカメラ
  • デュアルヘッドカメラ

第9章 アプリケーション別

  • 乳房スクリーニング
  • 乳房診断

第10章 エンドユーザー別

  • 病院
  • 診断センター
  • 専門クリニック
  • 学術研究機関
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • CMR Naviscan Corporation
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • SmartBreast Corporation
  • DIGIRAD HEALTH, INC.

第14章 付録

目次
Product Code: MI7378

Overview

Molecular breast imaging also known as scintimammography, nuclear medicine breast imaging and breast-specific gamma imaging, is an advanced and FDA-approved imaging technology that is used to identify breast cancer in women with dense breast tissue. Molecular breast imaging uses a special camera and a small amount of radioactive tracer to spotlight differences in tissue activity and differentiate healthy, dense tissue from breast irregularities. It is a highly accurate imaging study with a low chance of missing cancerous cells.

Moreover, a small amount of radioactive tracer is administered to the patient through an intravenous line. The tracer is swiftly absorbed by rapidly dividing cells, including cancer cells, and appears highlighted on imaging results. The patient places her breast on a special platform which is similar to that of a mammogram machine. The breast is gently compressed to capture high-quality images with a special gamma camera, but this light compression should not cause discomfort. The gamma cameras record the breast's tissue activity for about 20 minutes.

Market Dynamics: Drivers

Increasing adoption of molecular breast imaging for breast cancer screening

The increasing adoption of molecular breast imaging for breast cancer screening is expected to drive the market over the forecast period. Molecular breast imaging is known for its higher sensitivity in detecting breast cancer, particularly in women with dense breast tissue. It can help identify tumors that might be missed by mammography alone. This increased accuracy is a significant driver of its adoption.

Moreover, molecular breast imaging is often used as a complementary screening tool alongside mammography. Also, in cases where the mammograms yield inconclusive results or when additional information is needed, this imaging technique can provide valuable insights by reducing the risk of missed or delayed cancer diagnoses.

Ongoing advancements in this imaging technology have made it more accessible and easier to use. These technological improvements like the development of digital gamma cameras and more comfortable imaging procedures, make it a more attractive option. It is often recommended for high-risk patients such as those with a family history of breast cancer or known genetic mutations like BRCA1 and BRCA2. The ability to detect cancer at an earlier stage can be lifesaving for these individuals.

For instance, on February 9, 2021, SmartBreast Corporation released that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture Molecular Breast Imaging (MBI) systems. FITI has invested substantially in SmartBreast and will be the contract manufacturer for two MBI systems recently acquired by SmartBreast, the GE Healthcare Discovery NM 750b and the Dilon Technologies D6800. SmartBreast will rebrand the two systems as EVE CLEAR SCAN e750 and e680, respectively. Together, SmartBreast and FITI will co-develop and manufacture innovative, cost-effective, next-generation MBI systems to further increase the efficacy of detecting cancer in the earlier stage and to increase the adoption.

Further, the increasing prevalence of breast cancers, rising FDA approvals for novel and advanced molecular imaging techniques for breast, increasing clinical trials to develop more advanced devices, increasing awareness and advancements in the development of molecular breast imaging devices are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with molecular breast imaging, the high cost of associated with this imaging technique, this test can't detect all cancers and the tracer in the molecular breast imaging can develop allergic reactions are expected to hamper the market.

Segment Analysis

The global molecular breast imaging market is segmented based on design type, modality, application, end-user and region.

The gamma camera segment accounted for approximately 45.3% of the molecular breast imaging market share

The gamma camera segment is expected to hold the largest market share over the forecast period. The gamma camera in molecular breast imaging is mainly responsible for capturing images of the breast tissue after the injection of a radioactive tracer. It detects gamma rays emitted from the tracer, which is preferentially taken up by areas with increased metabolic activity, such as breast cancerous tumors.

Furthermore, the sensitivity of the gamma camera is crucial in detecting even small or low-activity tumors in the breast. This molecular breast imaging which consists of the gamma camera offers another option for women to be proactive about their breast health. Modern gamma cameras are designed for efficiency by allowing for quicker image acquisition and reduced radiation exposure for patients. Efficiency is a vital consideration, as it impacts patient comfort.

Additionally, the gamma cameras of molecular breast imaging often come equipped with advanced image processing and analysis software. These tools aid radiologists in interpreting the images, making the camera an integral part of the diagnostic process. The design and functionality of the gamma camera can significantly influence the patient's experience. A comfortable and well-designed camera can help reduce anxiety and improve the overall patient experience during the molecular breast imaging procedure.

Geographical Analysis

North America accounted for approximately 40.3% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is a hub for its strong presence of major players such as diagnostic companies and medical device companies. The presence of major players actively focusing on the development of more advanced molecular breast imaging by the technological advancements for better adoption along with better patient outcomes.

Furthermore, the increasing prevalence of breast cancer in the region is very high, which is considered to drive the market in the region. Due to the high prevalence of breast cancer in the region, it is known for the increased adoption for the diagnosis and screening of breast cancer. Early detection reduces the death rate of the patients by early detection and diagnosis.

For instance, according to the National Institute of Health (NIH), 2021, in the United States, there are over 250,000 new cases of breast cancer annually with over 46,000 women dying of the disease. Over the past two decades, the death rate from breast cancer has decreased by over 40%, a monumental achievement, due to the combination of improved detection as well as improved, increasingly targeted therapies. When breast cancer is detected early, over 95% of women survive more than five years.

Competitive Landscape

The major global players in the molecular breast imaging market include: CMR Naviscan Corporation, SmartBreast Corporation and DIGIRAD HEALTH, INC. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global molecular breast imaging market. During the pandemic, molecular breast imaging procedures are postponed or canceled temporarily due to the redirected focus on the pandemic and its associated risks. Molecular breast imaging experienced a drop in patient volumes as people postponed routine visits. The pandemic disrupted supply chains for the components and materials needed for molecular breast imaging systems. Delays in the manufacturing and distribution of these components affected the availability of these imaging equipment.

Market Segmentation

By Design Type

  • Radioactive Tracer
  • Special Camera

By Modality

  • Single Head Gamma Camera
  • Dual Head Camera

By Application

  • Breast Screening
  • Breast Diagnosis

By End-User

  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Academic and Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global molecular breast imaging market segmentation based on design type, modality, application, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of molecular breast imaging market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global molecular breast imaging market report would provide approximately 48 tables, 59 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Design Type
  • 3.2. Snippet by Modality
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption for Breast Cancer Screening
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with Molecular Breast Imaging
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Design Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 7.1.2. Market Attractiveness Index, By Design Type
  • 7.2. Radioactive Tracer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Gamma Camera

8. By Modality

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.1.2. Market Attractiveness Index, By Modality
  • 8.2. Single Head Gamma Camera*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Dual Head Camera

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Breast Screening*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Breast Diagnosis

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Diagnostic Centers
  • 10.4. Specialty Clinics
  • 10.5. Academic and Research Institutes
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.2.5. 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. CMR Naviscan Corporation*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. SmartBreast Corporation
  • 13.3. DIGIRAD HEALTH, INC.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us